Somatostatin CAS NO.51110-01-1

Somatostatin Basic information

Discovery Structure Gene, mRNA, and precursor Clinical implications Receptors Biological functions Regulation of synthesis and release
Product Name:    Somatostatin
Synonyms:    panhibin;M.W. 1637.80 C76H104N18O19S2;CCRIS 3629;Somatostatin;Anti-Somatostatin, N-Terminal antibody produced in rabbit;SOMATOSTATIN [GIF];SOMATOSTATIN (HUMAN, OVINE, PORCINE, RAT, MOUSE);SOMATOSTATIN (HUMAN, OVINE, PORCINE, RAT, MOUSE) 2ACOH 6H2O
CAS:    51110-01-1
MF:    C76H104N18O19S2
MW:    1637.88
EINECS:    256-969-7
Product Categories:    
Mol File:    51110-01-1.mol

Somatostatin Chemical Properties
storage temp.     −20°C
solubility     H2O: 1 mg/mL
form     powder

Safety Information
Hazard Codes     Xi
Risk Statements     36/37/38
Safety Statements     26-36
WGK Germany     3
RTECS     WF8751700
F     3-10-21

Description    Originally isolated from hypothalamic tissue, somatostatin is characterized as an inhibitor of growth hormone (GH) release. The structure was determined in 1971. Subsequent investigations led to the recognition that somatostatin also was released from the pancreas and has a role of inhibiting the secretion of both insulin and glucagon. A total of five somatostatin receptor subtypes have been characterized and cloned (sst1 to sst5). Subtype sst4 is associated with the inhibition of insulin release, and an sst4-selective inhibitor has been reported. The somatostatin analogue SOM230 has exhibited selectivity for sst1, sst2, sst3, and sst5 in rats and effectively decreased plasma GH and insulin-like growth factor-1 (IGF-1) levels by 75% without significant effects on insulin or glucagon. Another analogue, PT R3173, with selectivity for recombinant human somatostatin receptor (hsst2, hsst4, hsst5) was substantially more effective in inhibiting GH secretion compared to glucagon and insulin release in rats.
Uses    Somatostatin is a peptide hormone that regulates the endocrine system